All In Biotech

NDA 004782 · Wyeth Pharms

Premarin

Estrogens, Conjugated · Oral · Estrogen

Novel

Last checked: Nov 20, 2026Latest source record: Apr 22, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1942

May 8, 1942

Approved uses

3

Original approval plus efficacy supplements

Registered trials

1,166

241 Phase 3, 150 recruiting

FAERS reports

59,171

41,980 serious, 1,854 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, BREAST CANCER and PROBABLE DEMENTIA WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, BREAST CANCER and PROBABLE DEMENTIA See full prescribing information for complete boxed warning. Estrogen-Alone Therapy • There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens ( 5.2 ) • Estrogen-alone therapy should not be used for the prevention of cardiovascular disease or dementia ( 5.1 , 5.3 ) • Women's Health Initiative (WHI) estrogen-alone substudy reported increased risks of stroke and deep vein thrombosis (DVT) ( 5.1 ) • The WHI Memory Study (WHIMS) estrogen-alone ancillary study of WHI reported an increased risk of probable dementia in postmenopausal women 65 years of age and older ( 5.3 ) Estrogen Plus Progestin Therapy • Estrogen plus progestin therapy should not be used for the...

What it is approved for

From the label in effect Jun 4, 2026.

PREMARIN is a mixture of estrogens indicated for: • Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause ( 1.1 ) • Treatment of Moderate to Severe Vulvar and Vaginal Atrophy due to Menopause ( 1.2 ) • Treatment of Hypoestrogenism due to Hypogonadism, Castration or Primary Ovarian Failure ( 1.3 ) • Treatment of Breast Cancer (for Palliation Only) in Appropriately Selected Women and Men with Metastatic Disease ( 1.4 ) • Treatment of Advanced Androgen-Dependent Carcinoma of the Prostate (for Palliation Only) ( 1.5 ) • Prevention of Postmenopausal Osteoporosis ( 1.6 ) 1.1 Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause 1.2 Treatment of Moderate to Severe Symptoms of Vulvar and Vaginal Atrophy due to Menopause Limitations of Use When prescribing solely for the treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause, topical vaginal products should be considered. 1.3 Treatment of Hypoestrogenism due to Hypogonadism, Castration or Primary Ovarian Failure 1.4 Treatment of Breast Cancer (for Palliation Only) in Appropriately Selected Women and Men with Metastatic Disease 1.5 Treatment of Advanced Androgen-Dependent Carcinoma of the Prostate (for Palliation Only) 1.6 Prevention of Postmenopausal Osteoporosis Limitations of Use When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and non-estrogen medication should be carefully considered.

Mechanism: Endogenous estrogens are largely responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal intracellular human estrogen and is substantially more potent than its metabolites, estrone and estriol, at the receptor level. The primary source of estrogen in normally cycling adult women is the ovarian follicle, which secretes 70 to 500 mcg of estradiol daily, depending on the phase of the menstrual cycle. After...

Therapeutic areas: Endocrinology and women's health

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

6 products under this application
  • PREMARIN · ESTROGENS, CONJUGATED 2.5MG · TABLET, ORAL · Discontinued
  • PREMARIN · ESTROGENS, CONJUGATED 0.9MG · TABLET, ORAL · Prescription · TE AB
  • PREMARIN · ESTROGENS, CONJUGATED 0.3MG · TABLET, ORAL · Prescription · TE AB
  • PREMARIN · ESTROGENS, CONJUGATED 1.25MG · TABLET, ORAL · Prescription · TE AB
  • PREMARIN · ESTROGENS, CONJUGATED 0.45MG · TABLET, ORAL · Prescription · TE AB
  • PREMARIN · ESTROGENS, CONJUGATED 0.625MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Estrogens" as an intervention, any sponsor and status, largest first.

All 1,166 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • breast cancer9,643
  • breast cancer female8,869
  • drug ineffective3,442
  • nausea2,413
  • headache2,369
  • pain2,304
  • fatigue2,284
  • off label use2,231
  • dizziness1,686
  • breast cancer metastatic1,682
  • dyspnoea1,661
  • malaise1,616

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20044,156
20053,642
20063,215
20071,686
20083,634
20095,174
20109,123
20112,685
20122,581
20132,149
20142,043
20152,431
20162,530
20171,975
20181,787
20192,160
20202,285
20211,520
20221,402
20231,079
2024856
2025641
2026412

Recalls

1 FDA enforcement reports for this application.

  • Sep 15, 2016 · Class III · Terminated

    Labeling: Incorrect or Missing Lot and/or Exp Date: Bottles were incorrectly labeled with an expiry date of 11/17; the correct date is 09/17.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Premarin* (Estrogens, Conjugated)

2024 spending

$255M

Beneficiaries

231,894

610,592 claims

Per beneficiary

$1,100

$10.78 per unit

View as table
YearSpending
2020$298,132,949
2021$291,232,583
2022$281,548,605
2023$279,329,987
2024$254,990,018

Part B: Premarin (Estrogens, Conjugated) · HCPCS J1410

2024 spending

$28K

Beneficiaries

103

201 claims

Per beneficiary

$268

2024 ASP limit $377.83 per unit

View as table
YearSpending
2020$29,611
2021$30,866
2022$50,419
2023$27,894
2024$27,593

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,844 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.